Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.
Dapagliflozin在美國Medicare人口中對心腎代謝綜合症的成本抵銷。
Adv Ther 2024-07-03
The effect of Empagliflozin on echocardiographic parameters in diabetic patients after acute myocardial infarction: A systematic review and meta-analysis with trial sequential analysis.
糖尿病患者急性心肌梗塞後 Empagliflozin 對心臟超聲波參數的影響：一項系統性回顧和具有試驗序列分析的荟萃分析。
Ir J Med Sci 2024-07-03
Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study.
鈉葡萄糖共同轉運蛋白2抑制劑對2型糖尿病患者認知功能障礙風險的異質性治療效應：一項基於人群的cohort研究。
Alzheimers Dement 2024-07-03
Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
第二型糖尿病患者接受鈉葡萄糖共同轉運蛋白2抑製劑或葡萄糖樣肽-1受體激動劑治療後腎臟和代謝結果的長期比較。
BMC Med 2024-07-03
Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.
基線心電圖特徵對急性心肌梗塞後接受 Empagliflozin 治療的心臟生物標記和超聲心動圖指標變化的影響。
Sci Rep 2024-07-02
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.
冠狀動脈旁路移植術後 empagliflozin 預防心房纖維顫動效果的評估：雙盲、隨機、安慰劑對照試驗。
Naunyn Schmiedebergs Arch Pharmacol 2024-07-02